Skip to main content
SpringerLink
Log in

Current Status and Future Perspectives on Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy

  • Interventional Cardiology (S Rao, Section Editor)
  • Published:
Current Cardiology Reports Aims and scope Submit manuscript

Abstract

Hypertrophic cardiomyopathy (HCM) is the most common genetic cardiac disease. Patients may present with a wide variety of symptoms, ranging from relatively asymptomatic to heart failure, recurrent syncope, angina, or sudden death. Once diagnosed, a thorough clinical, anatomic and physiologic assessment should be undertaken. Treatment options include both pharmacologic and invasive therapies, with a goal to reduce symptoms and possibly extend longevity. Traditionally, the "gold standard" for treating severe obstructive HCM has been ventricular septal myotomy-myomectomy. Since its introduction in 1994, alcohol septal ablation (ASA) has emerged as an acceptable alternative in patients who meet strict anatomic criteria, and has been supported in recent guidelines. We review the indications, technique, competency requirements, alternatives, outcomes, complications, and future directions of ASA.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Fannapazir L, Epstein ND, Panza A, et al. Long-term results of dual chamber (DDD) pacing in obstructive hypertrophic cardiomyopathy: evidence for progressive symptomatic and hemodynamic improvement and reduction of left ventricular hypertrophy. Circulation. 1994;90:2731–42.

    Article  Google Scholar 

  2. Nishimura RA, Trusty JM, Hayes DL, et al. Dual-chamber pacing for hypertrophic cardiomyopathy: a randomized, double-blind, crossover trial. J Am Coll Cardiol. 1997;29:435–41.

    Article  CAS  PubMed  Google Scholar 

  3. McCully RB, Nishimura A, Rajik AJ, et al. Extent of clinical improvement after surgical treatment of hypertrophic obstructive cardiomyopathy. Circulation. 1996;94:467–71.

    Article  CAS  PubMed  Google Scholar 

  4. Sigwart U. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet. 1995;346:211–4.

    Article  CAS  PubMed  Google Scholar 

  5. Knight C, Kurbaan AS, Seggewiss H, et al. Nonsurgical septal reduction for hypertrophic obstructive cardiomyopathy: outcome in the first series of patients. Circulation. 1997;95:2075–81.

    Article  CAS  PubMed  Google Scholar 

  6. Durand E, Mousseaux E, Coste P, et al. Non-surgical septal myocardial reduction by coil embolization for hypertrophic obstructive cardiomyopathy: early and 6 months follow-up. Eur Heart J. 2008;29:348–55.

    Article  PubMed  Google Scholar 

  7. Emmel M, Sreeram N, de Giovanni JV, Brockmeier K. Radiofrequency catheter septal ablation for hypertrophic obstructive cardiomyopathy in childhood. Z Kardiol. 2005;94:699–703.

    Article  CAS  PubMed  Google Scholar 

  8. Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA guidelines for the diagnosis and treatment of hypertrophic cardiomyopathy. Circulation. 2011;124:2761–96. This document is the first US national guideline on HCM management, and fully outlines the indications and contraindications of invasive therapy, including both ASA and surgical myectomy. Subsets in whom ASA may be preferred, those in whom surgery is preferred, and those in whom both options are reasonable after a balanced and thorough discussion, are fully delineated.

  9. Harold JG, Bass TA, Bashore TM, Brindis RG, Brush JE Jr, Burke JA, et al. ACCF/AHA/SCAI 2013 update of the clinical competence statement on coronary artery interventional procedures: a report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Clinical Competence and Training (Writing Committee to Revise the 2007 Clinical Competence Statement on Cardiac Interventional Procedures). J Am Coll Cardiol. 2013;62:357–96. This statement, for the first time, outlines operator competency requirements for the performance of alcohol septal ablation.

  10. Holmes Jr DR, Valeti US, Nishimura RA. Alcohol septal ablation for hypertrophic cardiomyopathy: indications and technique. Catheter Cardiovasc Interv. 2005;66:375–89.

    Article  PubMed  Google Scholar 

  11. Gimeno JR, Tome T, McKenna WJ. Alcohol septal ablation in hypertrophic cardiomyopathy: an opportunity to be taken. Rev Esp Cardiol. 2012;65:314–8.

    Article  PubMed  Google Scholar 

  12. Ommen SR, Maron BJ, Olivotto I, Maron MS, Cecchi F, Betocchi S, et al. Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2005;46:470–6.

    Article  PubMed  Google Scholar 

  13. Woo A, Williams WG, Choi R, Wigle ED, Rozenblyum E, Fedwick K, et al. Clinical and echocardiographic determinants of long-term survival after surgical myectomy in obstructive hypertrophic cardiomyopathy. Circulation. 2005;111:2033–41.

    Article  PubMed  Google Scholar 

  14. Agarwal S, Tuzcu EM, Desai MY, Smedira N, Lever HM, Lytle BW, et al. Updated meta-analysis of septal alcohol ablation vs myectomy for hypertrophic cardiomyopathy. J Am Coll Cardiol. 2010;55:823–34.

    Article  PubMed  Google Scholar 

  15. Moon JC, McKenna WJ, McCrohon JA, Elliott PM, Smith GC, Pennell DJ. Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. J Am Coll Cardiol. 2003;41:1561–7.

    Article  PubMed  Google Scholar 

  16. Dumont CA, Monserrat L, Soler R, Rodriguez E, Fernandez X, Peteiro J, et al. Significado clínico del realce tardío de gadolinio con resonancia magnética en pacientes con miocardiopatía hipertrófica. Rev Esp Cardiol. 2007;60:15–23.

    Article  PubMed  Google Scholar 

  17. Seggewiss H, Faber L, Ziemssen P, Gleichmann U. One-year follow-up after echocardiographically-guided percutaneous septal ablation in hypertrophic obstructive cardiomyopathy. Dtsch Med Wochenschr. 2001;126:424–30.

    Article  CAS  PubMed  Google Scholar 

  18. Alam M, Dokainish H, Lakkis NM. Hypertrophic obstructive cardiomyopathy-alcohol septal ablation vs myectomy: a meta-analysis. Eur Heart J. 2009;30:1080–7.

    Article  PubMed  Google Scholar 

  19. Agarwal S, Tuzcu EM, Desai MY, Smedira N, Lever HM, Lytle BW, et al. Updated meta-analysis of septal alcohol ablation vs myectomy for hypertrophic cardiomyopathy. J Am Coll Cardiol. 2010;55:823–34. This study is one of many that appear to confirm comparable clinical efficacy between surgical myectomy and alcohol septal ablation.

  20. Olivotto I, Ommen SR, Maron MS, Cecchi F, Maron BJ. Surgical myectomy vs alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Will there ever be a randomized trial? J Am Coll Cardiol. 2007;50:831–4.

    Article  PubMed  Google Scholar 

  21. Sorajja P, Valeti U, Nishimura RA, Ommen SR, Rihal CS, Gersh BJ, et al. Outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Circulation. 2008;118:131–9.

    Article  PubMed  Google Scholar 

  22. Sorajja P, Binder J, Nishimura RA, Holmes Jr DR, Rihal CS, Gersh BJ, et al. Predictors of an optimal clinical outcome with alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Catheter Cardiovasc Interv. 2013;81:E58–67.

    Article  PubMed  Google Scholar 

  23. Leonardi RA, Kransdorf EP, Simel DL, Wang A. Meta-analyses of septal reduction therapies for obstructive hypertrophic cardiomyopathy: comparative rates of overall mortality and sudden cardiac death after treatment. Circ Cardiovasc Interv. 2010;3:97–104. This study showed that alcohol septal ablation and surgical myectomy may have similar survival and SCD rates, and that ASA may be statistically superior.

  24. ten Cate FJ, Soliman OI, Michels M, Theuns DA, de Jong PL, Geleijnse ML, et al. Long-term outcome of alcohol septal ablation in patients with obstructive hypertrophic cardiomyopathy: a word of caution. Circ Heart Fail. 2010;3:362–9.

    Article  PubMed  Google Scholar 

  25. Jensen MK, Prinz C, Horstkotte D, van Buuren F, Bitter T, Faber L, et al. Alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy: low incidence of sudden cardiac death and reduced risk profile. Heart. 2013;99:1012–7.

    Article  PubMed  Google Scholar 

  26. Sorajja P, Ommen SR, Holmes Jr DR, et al. Survival after alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Circulation. 2012;126:2374–80.

    Article  PubMed  Google Scholar 

  27. Veselka J, Lawrenz T, Stellbrink C, Zemanek D, Branny M, Januska J, et al. Early outcomes of alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a European multicenter and multinational study. Catheter Cardiovasc Interv. 2013. [Epub ahead of print]. This study confirmed a <1 % in-hospital mortality after ASA in the current era, similar to that seen in the North American Registry.

  28. Zemanek D, Svab P, Veselka J. Power Doppler myocardial contrast echocardiography in alcohol septal ablation for hypertrophic obstructive cardiomyopathy. Clin Cardiol. 2010;33:E82.

    Article  PubMed  Google Scholar 

  29. Fifer MA, Sigwart U. Controversies in cardiovascular medicine. Hypertrophic obstructive cardiomyopathy: alcohol septal ablation. Eur Heart J. 2011;32:1059–64.

    Article  PubMed  Google Scholar 

  30. Nagueh SF, Groves BM, Schwartz L, et al. Alcohol septal ablation for the treatment of hypertrophic obstructive cardiomyopathy: a multicenter North American Registry. J Am Coll Cardiol. 2011;58:2322–8. This observational study is the largest US experience to date, and documents sustained clinical efficacy and low procedural mortality <1 %.

  31. Ball W, Ivanov J, Rakowski H, et al. Long-term survival in patients with resting obstructive hypertrophic cardiomyopathy: comparison of conservative vs invasive treatment. J Am Coll Cardiol. 2011;58:2313–21.

    Article  PubMed  Google Scholar 

  32. Fernandes VL, Nagueh SF, Wang W, Roberts R, Spencer III WH. A prospective follow-up of alcohol septal ablation for symptomatic hypertrophic obstructive cardiomyopathy—the Baylor experience (1996–2002). Clin Cardiol. 2005;28:124–30.

    Article  PubMed  Google Scholar 

Download references

Compliance with Ethics Guidelines

ᅟ

Conflict of Interest

R. N. Khouzam and S. S. Naidu declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Department of Medicine, Division of Cardiovascular Diseases, University of Tennessee Health Science Center, Memphis, TN, USA

    Rami N. Khouzam & Srihari S. Naidu

  2. Department of Medicine, Division of Cardiology, Winthrop University Hospital, 120 Mineola Blvd, Suite 500, Mineola, NY, 11501, USA

    Srihari S. Naidu

Authors
  1. Rami N. Khouzam
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Srihari S. Naidu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Srihari S. Naidu.

Additional information

This article is part of the Topical Collection on Interventional Cardiology

Rights and permissions

Reprints and permissions

About this article

Cite this article

Khouzam, R.N., Naidu, S.S. Current Status and Future Perspectives on Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy. Curr Cardiol Rep 16, 478 (2014). https://doi.org/10.1007/s11886-014-0478-3

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11886-014-0478-3

Keywords

Search

Navigation